Study of Metabolic, Transcriptomic and Proteomic Characteristics in Relapsed Glioblastoma

NCT06430424 | Recruiting

• 1 other identifier: CHUBX 2023/79
• Study Type: observational
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

Glioblastomas are the most frequent and aggressive malignant tumors of the CNS in adults, with almost systematic relapse despite treatment with surgery followed by radio-chemotherapy (STUPP protocol). The aim of this study is to better characterize transcriptomic, proteomic and metabolic changes in relapsed glioblastoma compared to the initial tumor, in order to identify new prognostic markers and potential new therapeutic targets.

Conditions

Relapsed Cancer; Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype

Keywords

Recurrent glioblastoma; Prognostic; Metabolism; Proteomic; Transcriptomic; Microbiota

Outcome Measures

Primary Outcomes (1)

• Evaluation of metabolic changes involved in glioblastoma relapse

  Relative abondance of metabolite and differential enzyme expression in a recurrence versus primary sample

  Up to 2 years after the start of the study

Secondary Outcomes (2)

• Progression-free survival

  From date of the second surgery until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years

• Overall survival

  From date of the second surgery until the date of death from any cause, assessed up to 5 years

Study Arms (1)

Patients operated for primary and recurrent glioblastoma

Patients operated for both primary and recurrent glioblastoma between 2005 and 2023 at the CHU de Bordeaux

Biological: Relapsed glioblastoma

Interventions

Relapsed glioblastoma BIOLOGICAL

Paired tumor samples diagnosis/relapse

Patients operated for primary and recurrent glioblastoma

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with relapsed glioblastomas reoperated at the University Hospital of Bordeaux, France, between 2005 and 2023, for which tumor material is available

You may qualify if:

• age \> 18 years
• surgery for both primary and recurrent glioblastoma between 2005 and 2023 at the CHU de Bordeaux

You may not qualify if:

• systemic therapy received for non-glioblastoma tumor

Sponsors & Collaborators

• University Hospital, Bordeaux: lead

Study Sites (1)

CHU de Bordeaux - Hôpital Saint-André, Service d'Oncologie Médicale

Bordeaux, 33000, France

RECRUITING

MeSH Terms

Conditions

Recurrence; Glioblastoma

Condition Hierarchy (Ancestors)

Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Astrocytoma; Glioma; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue

Central Study Contacts

Mathieu LARROQUETTE

CONTACT

+33 5 56 79 58 08; mathieu.larroquette@chu-bordeaux.fr

Julien ENGELHARDT

CONTACT

julien.engelhardt@chu-bordeaux.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 27, 2024
• First Posted: May 28, 2024
• Study Start: April 5, 2024
• Primary Completion: July 1, 2025
• Study Completion: April 1, 2026
• Last Updated: July 30, 2025

Record last verified: 2025-07

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)